Thrombotic microangiopathy during carfilzomib use: case series in Singapore. - Wikidata - wikimedia - TriplyDB

Thrombotic microangiopathy during carfilzomib use: case series in Singapore.

Thrombotic microangiopathy during carfilzomib use: case series in Singapore.

http://www.wikidata.org/entity/Q37271015

about

Thrombotic microangiopathy during carfilzomib use: case series in Singapore.

http://www.wikidata.org/entity/Q37271015

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Thrombotic microangiopathy during carfilzomib use: case series in Singapore.

@en

Thrombotic microangiopathy during carfilzomib use: case series in Singapore.

@nl

type

label

Thrombotic microangiopathy during carfilzomib use: case series in Singapore.

@en

Thrombotic microangiopathy during carfilzomib use: case series in Singapore.

@nl

prefLabel

Thrombotic microangiopathy during carfilzomib use: case series in Singapore.

@en

Thrombotic microangiopathy during carfilzomib use: case series in Singapore.

@nl

P1433

Q37271015-4DFFEC73-87C3-40AB-91B6-02E64FF7A635

P1476

Q37271015-76B10E20-B9B5-4AB5-B438-DF74C71ED54D

P2093

Q37271015-0EE8BA9F-7A85-4716-8D73-F09DBBB2F400

Q37271015-26429F20-676C-4259-BD57-68D9014A7CE9

Q37271015-30656714-3623-4396-888E-CB3C1CEB5379

Q37271015-5F26ACD9-930A-4291-BFEA-97EDC16ADCCA

Q37271015-843CB06B-266A-41F3-A44D-4792B3DB01A4

Q37271015-8AD27ABC-B088-474D-9D54-C2E13812B9D0

Q37271015-8CBE0F85-398A-4F0A-A195-A94F3251C1E0

Q37271015-A2182BDD-70CD-45AD-AF93-F36746E941A9

Q37271015-B138ED58-F401-4C06-B6C8-FE7C4985C017

Q37271015-C4F3B8A5-D734-4090-BCCC-1754D6C46DE3

P2860

Q37271015-03AE7202-03A5-4A0D-A3EC-783A396A74E1

Q37271015-23E0BADC-F3AA-4A5A-B42E-902950CE7178

Q37271015-38F54100-8D9C-4CC4-BDDE-53E359F4EDC1

Q37271015-62089F0E-FC73-4838-AEE5-7E73FE5CA753

Q37271015-6E94660F-BD83-4A89-B0CC-5FD2AE4663CC

Q37271015-78805B73-FE2F-45D1-A0DE-61A91238705C

Q37271015-9DC9171F-93BD-463E-9BF1-0A143E0AE14F

Q37271015-A81AF29F-1F96-4E4C-A2F3-567E1482AE63

Q37271015-B3D08697-3104-4F71-8E6C-45E7F099EE79

Q37271015-BF164CEB-67B7-459B-BDC8-F6A4725191A0

P2888

Q37271015-BBF30742-2B14-4BEB-BF41-9B49C96E3EA9

P304

Q37271015-32E2E87B-D7A9-4600-B1AA-F69D8BEA4604

P31

Q37271015-657B6AF9-7C40-4963-99B5-CD410FC07F37

P356

Q37271015-0FCEEDBB-C084-4922-BB65-E3585E2265D2

P433

Q37271015-CA2F86CE-7488-45D1-8FE1-EED4B95A741F

P478

Q37271015-B45AD9B8-EBF1-414C-9C98-8F9046918ADF

P577

Q37271015-E33AB159-595E-4771-9318-8C33E12B3863

P698

Q37271015-B0E7CB4F-B60B-4DFE-AB03-BAC54880F9CC

P921

Q37271015-719176C6-4283-4BCF-BFFB-D61E6A2753F0

P932

Q37271015-3FB98BB3-0319-49EF-A938-5B60578D52DB

P356

P1433

Blood Cancer Journal

P1476

Thrombotic microangiopathy during carfilzomib use: case series in Singapore.

@en

P2093

A Lin

http://www.w3.org/2001/XMLSchema#string

C Nagarajan

http://www.w3.org/2001/XMLSchema#string

C Phipps

http://www.w3.org/2001/XMLSchema#string

E M Teh

http://www.w3.org/2001/XMLSchema#string

J Lee

http://www.w3.org/2001/XMLSchema#string

M Ooi

http://www.w3.org/2001/XMLSchema#string

N F Grigoropoulos

http://www.w3.org/2001/XMLSchema#string

S F Lim

http://www.w3.org/2001/XMLSchema#string

S K Gopalakrishnan

http://www.w3.org/2001/XMLSchema#string

S Surendran

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF inhibition and renal thrombotic microangiopathy

Thrombotic microangiopathy associated with proteasome inhibitors

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

Carfilzomib: a novel second-generation proteasome inhibitor

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.

U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.

Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

P2888

P304

e450

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BCJ.2016.62

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27471866

http://www.w3.org/2001/XMLSchema#string

P921

P932

5030383

http://www.w3.org/2001/XMLSchema#string